At least nine dominant neurodegenerative diseases are caused by expansion of CAG trinucleotide repeats, resulting in the synthesis of proteins containing long, toxic polyglutamine repeats. The most prominent, Huntington's disease, is caused by expansion of CAG trinucleotide repeats in the first exon of the HTT gene, which is essential for both development and neurogenesis. Most Huntington's disease patients carry one normal allele containing 6 to B35 CAG triplets (average, 18) and a mutant, disease-causing allele containing 436 CAG triplets (average, 42) 1, 2 . The resulting mutant HTT protein causes selective loss of neurons. Half the wild-type amount of HTT protein suffices for normal development and neuronal function in an adult [3] [4] [5] [6] . In theory, triplet expansion diseases such as Huntington's disease could be treated by using small interfering RNAs (siRNA) to selectively silence the allele containing the expanded CAG repeat. Because siRNAs targeting the CAG repeat cannot discriminate between the mutant and normal alleles 7 , we have previously proposed to silence the mutant allele using siRNAs that can discriminate between the two isoforms of a single nucleotide polymorphism (SNP) [8] [9] [10] . Such an siRNA would fully match the disease allele, reducing its expression, but would mismatch with the nucleotide present at the SNP site in the normal HTT mRNA 9, 11 .
The basis for the design of disease allele-specific siRNAs is the linkage of a heterozygous SNP to the expanded CAG repeat, which is spatially far removed from the SNP, in the individual Huntington's disease patient. The method described here, SNP linkage by circularization (SLiC), provides this linkage. The standard method for linking SNPs to inherited, dominant disease-causing genes is pedigree analysis, which requires molecular testing of close relatives of the patient. For Huntington's disease, these are likely to be the unaffected parent and at-risk siblings or children. In the US, fears of loss of health insurance by at-risk relatives 12 and uncertainty about paternity complicate pedigree testing. SLiC avoids these complications because only the Huntington's disease patient need be genetically tested.
The HTT locus is large, spanning 180 kilobases (kb) on the short arm of chromosome 4, and produces two mRNA isoforms, 10 and 13 kb, by alternative splicing 4 . There are 16 SNP sites in the normal HTT mRNA with substantial heterozygosity (Supplementary Table 1 online) . If the rates of heterozygosity are similar in Huntington's disease patients, the vast majority of patients will have at least one heterozygous SNP and could be treated by at least one of the pairs of siRNAs. However, most candidate SNP sites are in exons 25, 29, 39, 47, 48, 50, 57, 60, 61 and 67, thousands of base pairs distal to the CAG expansion (Fig. 1a) . Thus, the challenge to identify linkage between a particular SNP isoform and the expanded CAG repeat is the length of the HTT mRNA.
Our strategy juxtaposes the CAG repeats and the distant SNP site by first circularizing the DNA to produce a single PCR amplicon that can be easily sequenced (Fig. 1b and Supplementary Methods online). We extracted total RNA from Huntington's disease patient tissue samples, reverse-transcribed it using a primer flanking the SNP site to be interrogated and then amplified the cDNA by longrange PCR using a pair of primers, one 5¢ to the CAG repeats and one 3¢ to the SNP (Supplementary Table 2 online). We then used intramolecular ligation to circularize the long, rare cDNA generated by PCR. Finally, we generated a small amplicon comprising the CAG repeat juxtaposed to the SNP site by inverse PCR. This final amplicon was sufficiently small that the PCR products from the normal and disease-causing alleles could be readily separated by agarose gel electrophoresis according to their CAG repeat lengths. We identified the SNP-(CAG) n linkage by directly sequencing each PCR product.
HTT is ubiquitously expressed in human tissues, including peripheral blood lymphocytes 13 . We therefore used Huntington's disease patient blood samples to validate the SLiC method; the human subjects committee of Massachusetts General Hospital (IRB 2003P000395) and the University of Massachusetts Medical School (Docket 12464) approved blood sampling of patients and control subjects, all of whom gave written consent. We purified lymphocytes from Huntington's disease patient blood, cultured them for 3-4 d, and then synthesized full-length HTT first-strand cDNA from the total RNA extracted from the lymphocytes. To verify fulllength cDNA production, we used the first-strand cDNA to PCRamplify a 180-base pair region of exon 1 encompassing the CAG repeats. Exon 1 was successfully amplified from both alleles (Fig. 1c) , establishing that our protocol yielded full-length cDNA for both mutant and normal HTT mRNA. We also used the firststrand cDNA to PCR amplify across each candidate SNP site to establish which SNPs were heterozygous in each patient assayed. Direct sequencing of the PCR products established that the SNP heterozygosity separately deduced from cDNA and genomic DNA matched for all 11 sites examined (Supplementary Table 3 online).
Next we used long-range PCR to amplify a region of the cDNA beginning 5¢ to the CAG repeats in exon 1 and ending 3¢ to the candidate SNP site, a distance spanning 3.3-10.9 kilobases for the SNP sites to be interrogated. The CAG repeats and the SNP site are near the opposite ends of this amplicon. The PCR primers used in this reaction introduce KasI restriction sites, which we subsequently used to join the ends of the PCR product. We purified the PCR products together from a 0.9% agarose gel (Fig. 1d) .
Intramolecular circularization of the long range PCR products is central to our method. We used KasI sites because there are no KasI sites in any of the large amplicons spanning exon 1 to the downstream SNP sites we interrogated. KasI digestion of the long-range PCR products created cohesive ends that we then joined in dilute solution using Escherichia coli DNA ligase. To find the optimal DNA concentration for circularization, we first diluted KasI-digested cDNA (from exon 1 to exon 29; Fig. 1d ; 0.1 mg) to 10, 1 and 0.1 ng/ml and ligated the products using E. coli ligase under conditions that favor the formation of circles 14 . At 0.1 ng/ml, most of the cDNA migrated faster than expected for a linear monomer, indicating it was circular (Fig. 1e) . In a second round of optimization we examined concentrations from 1 to 0.016 ng/ml. The resulting intramolecular ligation products served as template for inverse PCR using a forward primer complementary to a region within exon 29, upstream of the heterozygous SNP site, and a reverse primer complementary to a site in exon 1. The products from the two alleles were readily separated; as little as 0.03 ng/ml of KasI-digested cDNA sufficed to template inverse PCR (Fig. 1f) . We gel-purified and sequenced the inverse PCR products to obtain the desired SNP-(CAG) n linkage information. As a final improvement to the protocol, we incubated the KasI-digested, E. coli DNA ligasetreated cDNA with exonuclease V to degrade linear DNA, including undesirable intermolecular ligation products. To test the optimized SLiC protocol, we interrogated eight different SNP sites in nine Huntington's disease patients (Fig. 1g and Supplementary Tables 1  and 3 ), establishing their linkage to the disease allele of HTT (Fig. 2) .
Because our method requires only peripheral blood, it can be used as a diagnostic technique for patient-specific therapeutic RNA interference, but the method is applicable to any tissue sample in which HTT is expressed. For example, we used the method on two frozen post-mortem brain samples to identify their SNP-(CAG) n linkages. SLiC avoids traditional cloning techniques that are cumbersome for large mRNAs such as HTT, reducing cost and effort, and which are unlikely to prove robust in a clinical setting. The method is rapid, allowing identification of allelic linkage between the CAG repeats and heterozygous SNP sites in less than two weeks (Supplementary Table 4 online). Prescreening for heterozygosity by direct sequencing of PCR amplicons spanning a panel of SNPs should streamline the process 15 . For patient tissue samples with multiple heterozygous SNP sites, the method can identify linkages among the heterozygous SNPs, providing haplotype information. The SNP-(CAG) n linkage for a patient also makes it possible to examine the individual expression of the two alleles. Thus, one could test whether the mutant, disease-causing mRNA accumulates differentially or whether the expression ratio of mutant mRNA to normal affects age of Huntington's disease onset or the speed of disease progression. Our method can be used to investigate SNP-(CAG) n linkage for any trinucleotide repeat diseases or for any two alleles of a gene that differ by insertion or deletion in which SNP sites of interest are distant from the site of mutation.
Note: Supplementary information is available on the Nature Methods website. 
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